TY - JOUR
T1 - pH protective Y 1 receptor ligand functionalized antiphagocytosis BPLP-WPU micelles for enhanced tumor imaging and therapy with prolonged survival time
AU - Jiang, Zhenqi
AU - Tian, Yuchen
AU - Shan, Dingying
AU - Wang, Yinjie
AU - Gerhard, Ethan
AU - Xia, Jianbi
AU - Huang, Rong
AU - He, Yan
AU - Li, Aiguo
AU - Tang, Jianchao
AU - Ruan, Huimin
AU - Li, Yong
AU - Li, Juan
AU - Yang, Jian
AU - Wu, Aiguo
N1 - Funding Information:
This work was supported by Youth Innovation Promotion Association Foundation, CAS ( 2017340 to Juan Li), Science Technology Department of Zhejiang Province ( 2016C33093 to Juan Li), Natural Science Foundation of China (Grant No. 51303196 to Juan Li, U1432114 to Aiguo Wu), Special Program for Applied Research on Super Computation of the NSFC-Guangdong Joint Fund (the second phase) ( U1501501 to Juan Li and Aiguo Wu), the Science & Technology Bureau of Ningbo City ( 2015C50004 , 2015B11002 , and 2017C110022 ), Zhejiang Province Financial Supporting ( 2017C03042 , LY18H180011 ), and CAS Interdiscipline Innovation Team . We acknowledge Miss. Siqi Wang and Dr. Jianhua Wang from Ningbo University Hospital for their help in hematological analysis. We thank Miss. Ruifen Zou for her help in animal experiments and Mr. Xuzhe Zhang from Beijing Dryas Pharma-Tech Co., Ltd. for his help of in data analysis of pharmacokenetics. Furthermore, the authors also acknowledge Shanghai Synchrotron Radiation Facility at Line BL15U (No. h15sr0021) used for X-ray fluorescence imaging and BL19U2 used for small-angle X-ray scattering, and National Synchrotron Radiation Laboratory in Hefei used for soft X-ray imaging (No. 2016-HLS-PT-002193).
Funding Information:
This work was supported by Youth Innovation Promotion Association Foundation, CAS (2017340 to Juan Li), Science Technology Department of Zhejiang Province (2016C33093 to Juan Li), Natural Science Foundation of China (Grant No. 51303196 to Juan Li, U1432114 to Aiguo Wu), Special Program for Applied Research on Super Computation of the NSFC-Guangdong Joint Fund (the second phase) (U1501501 to Juan Li and Aiguo Wu), the Science & Technology Bureau of Ningbo City (2015C50004, 2015B11002, and 2017C110022), Zhejiang Province Financial Supporting (2017C03042, LY18H180011), and CAS Interdiscipline Innovation Team. We acknowledge Miss. Siqi Wang and Dr. Jianhua Wang from Ningbo University Hospital for their help in hematological analysis. We thank Miss. Ruifen Zou for her help in animal experiments and Mr. Xuzhe Zhang from Beijing Dryas Pharma-Tech Co., Ltd. for his help of in data analysis of pharmacokenetics. Furthermore, the authors also acknowledge Shanghai Synchrotron Radiation Facility at Line BL15U (No. h15sr0021) used for X-ray fluorescence imaging and BL19U2 used for small-angle X-ray scattering, and National Synchrotron Radiation Laboratory in Hefei used for soft X-ray imaging (No. 2016-HLS-PT-002193).
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/7
Y1 - 2018/7
N2 - Nanoparticle-based tumor therapies are extensively studied; however, few are capable of improving patient survival time due to premature drug leakage, off target effects, and poor tissue penetration. Previously, we successfully synthesized a novel family of Y 1 receptor (Y 1 R) ligand modified, photoluminescent BPLP nanobubbles and nanoparticles for targeted breast cancer ultrasound imaging; however, increased accumulation could also be observed in the liver, kidney, and spleen, suggesting significant interaction of the particles with macrophages in vivo. Herein, for the first time, we imparted antiphagocytosis capability to Y 1 R ligand functionalized BPLP-WPU polymeric micelles through the incorporation of a CD47 human glycoprotein based self-peptide. Application of self-peptide modified, DOX loaded micelles in vivo resulted in a 100% survival rate and complete tumor necrosis over 100 days of treatment. In vivo imaging of SPION loaded, self-peptide modified micelles revealed effective targeting to the tumor site while analysis of iron content demonstrated reduced particle accumulation in the liver and kidney, demonstrating reduced macrophage interaction, as well as a 2-fold increase of particles in the tumor. As these results demonstrate, Y 1 R ligand, self-peptide modified BPLP-WPU micelles are capable of target specific cancer treatment and imaging, making them ideal candidates to improve survival rate and tumor reduction clinically.
AB - Nanoparticle-based tumor therapies are extensively studied; however, few are capable of improving patient survival time due to premature drug leakage, off target effects, and poor tissue penetration. Previously, we successfully synthesized a novel family of Y 1 receptor (Y 1 R) ligand modified, photoluminescent BPLP nanobubbles and nanoparticles for targeted breast cancer ultrasound imaging; however, increased accumulation could also be observed in the liver, kidney, and spleen, suggesting significant interaction of the particles with macrophages in vivo. Herein, for the first time, we imparted antiphagocytosis capability to Y 1 R ligand functionalized BPLP-WPU polymeric micelles through the incorporation of a CD47 human glycoprotein based self-peptide. Application of self-peptide modified, DOX loaded micelles in vivo resulted in a 100% survival rate and complete tumor necrosis over 100 days of treatment. In vivo imaging of SPION loaded, self-peptide modified micelles revealed effective targeting to the tumor site while analysis of iron content demonstrated reduced particle accumulation in the liver and kidney, demonstrating reduced macrophage interaction, as well as a 2-fold increase of particles in the tumor. As these results demonstrate, Y 1 R ligand, self-peptide modified BPLP-WPU micelles are capable of target specific cancer treatment and imaging, making them ideal candidates to improve survival rate and tumor reduction clinically.
UR - http://www.scopus.com/inward/record.url?scp=85047388208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047388208&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2018.04.002
DO - 10.1016/j.biomaterials.2018.04.002
M3 - Article
C2 - 29653288
AN - SCOPUS:85047388208
SN - 0142-9612
VL - 170
SP - 70
EP - 81
JO - Biomaterials
JF - Biomaterials
ER -